Quantcast

Latest Gene therapy Stories

2014-05-28 16:26:41

Groundbreaking Nature Publication Describes Successful ZFN Driven Genome Editing in Long-Term Repopulating Stem Cells Necessary for Clinical Translation RICHMOND, Calif., May 28, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in Nature of data demonstrating efficient zinc finger nuclease (ZFN)-mediated, targeted gene insertion that resulted in correction of the genetic defect in stem cells from an individual with X-linked severe combined...

2014-05-27 16:25:11

Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of rare, debilitating diseases, today announced the successful completion of a $72.8 million Series B financing led by Sofinnova Ventures. Joining Sofinnova as new investors in the company are Brookside...

2014-05-27 15:22:17

Aarhus University Aarhus University has developed a technology that uses the HIV virus as a tool in the fight against hereditary diseases For the first time researchers have succeeded in altering HIV virus particles so that they can simultaneously, as it were, 'cut and paste' in our genome via biological processes. Developed at the Department of Biomedicine at Aarhus University, the technology makes it possible to repair genomes in a new way. It also offers good perspectives for...

2014-05-27 08:28:00

SB-728-T-Treated Subject Maintains Control of Viral Load for 45 Weeks Without Anti-Retroviral Drugs RICHMOND, Calif., May 27, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) were outlined in several presentations and posters at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) from May 21-24, 2014....

2014-05-22 23:03:22

Transparency Market Research added a new report "Global Gene Therapy Market: Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report - http://www.transparencymarketresearch.com/gene-therapy-market.html. Albany, New York (PRWEB) May 22, 2014 Gene therapy involves use of DNA as a pharmaceutical agent to treat diseases. It is one of the most important developments in the field of medicine that has potential to treat various...

2014-05-22 08:29:48

In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ -- Tocagen Inc. today announced multiple scientific contributions at the American Society of Gene and Cell Therapy (ASGCT) 17(th) Annual Meeting, held May 21 to 24, 2014 at the Marriott Wardman Park in Washington, DC. At the ASGCT Annual Meeting, data from clinical and preclinical studies of Toca 511 will be presented in two podium presentations:...

2014-05-14 08:31:21

RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) will be presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fourteen oral and poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs...

2014-05-13 08:33:50

Gene therapy leader will house business operations and manufacturing in a growing and dynamic biotech hub PHILADELPHIA, May 13, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, announced today that it has signed a real estate agreement to open its permanent headquarters in West Philadelphia. Spark, which was spun out of Children's Hospital of Philadelphia in October 2013 along with a $50 million...

2014-05-05 12:29:33

MOUNTAIN VIEW, Calif., May 5, 2014 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced that it has partnered with Vectalys SAS to combine Clontech's Living Colors® fluorescent protein and Tet-On® 3G technologies with Vectalys' expertise in providing the highest quality ready-to-use lentiviral particles as vectors for gene delivery. http://photos.prnewswire.com/prnvar/20131021/SF99259LOGO Carol Lou, General Manager of Clontech...

2014-05-05 08:28:53

TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related